menu
    • menu
    [{"orgOrder":0,"company":"Epigenic Therapeutics","sponsor":"Morningside Venture Capital","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Epigenic Therapeutics Raises $20 Million in Series Angel and Pre-A Funding to Advance Next Generation Gene Editing Therapy","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Financing","leadProduct":"Epigenetic Therapy","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Epigenic Therapeutics","amount2":0.02,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Epigenic Therapeutics \/ Morningside Venture Capital","highestDevelopmentStatusID":"4","companyTruncated":"Epigenic Therapeutics \/ Morningside Venture Capital"},{"orgOrder":0,"company":"Epigenic Therapeutics","sponsor":"Qiming Venture Partners","pharmaFlowCategory":"D","amount":"$32.0 million","upfrontCash":"Undisclosed","newsHeadline":"Epigenic Therapeutics Announces $32 Million in Series A Funding to Bring Breakthrough Epigenome Medicine to Clinical Development","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Epigenic Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Epigenic Therapeutics \/ Qiming Venture Partners","highestDevelopmentStatusID":"4","companyTruncated":"Epigenic Therapeutics \/ Qiming Venture Partners"}]

    Find Clinical Drug Pipeline Developments & Deals by Epigenic Therapeutics

    Menu

    Epigenic Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Epigenic Therapeutics

                            China arrow
                            Discovery on Target
                            Not Confirmed

                            Epigenic Therapeutics

                            China arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Preclinical

                            Sponsor : Qiming Venture Partners

                            Deal Size : $32.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Epigenic Therapeutics Announces $32 Million in Series A Funding to Bring Breakthrough Epigenome Medicine to Cl...

                            Details : The proceeds will support the preclinical development and early clinical validation of two leading programs developed by platform EPIREG which employs its own AI algorithms to explore and obtain an optimized CRISPR-Cas component to regulate target gene a...

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            August 29, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Qiming Venture Partners

                            Deal Size : $32.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Epigenic Therapeutics

                            China arrow
                            Discovery on Target
                            Not Confirmed

                            Epigenic Therapeutics

                            China arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epigenetic Therapy

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Preclinical

                            Sponsor : Morningside Venture Capital

                            Deal Size : $20.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Epigenic Therapeutics Raises $20 Million in Series Angel and Pre-A Funding to Advance Next Generation Gene Edi...

                            Details : Proceeds of financing will be used to validate advances of the Company's proprietary epigenetic editing in non-human primates, expand expertise and capabilities, and sponsor early-stage clinical investigations.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            August 06, 2022

                            Lead Product(s) : Epigenetic Therapy

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Preclinical

                            Sponsor : Morningside Venture Capital

                            Deal Size : $20.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth